Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Hypoxia-inducible Transcription Factors Trigger Metastasis in Malignant Melanoma Tumors

By BiotechDaily International staff writers
Posted on 06 May 2013
Cancer researchers have linked the hypoxia-inducible transcription factors HIF1 and HIF2 to the processes that control metastasis in melanoma tumors.

Hypoxia-inducible factors (HIFs) are transcription factors that respond to changes in available oxygen in the cellular environment, specifically, to decreases in oxygen, or hypoxia. HIFs promote the activation of genes involved in cancer initiation, progression, and metastases. Hypoxia has been shown to enhance the invasiveness and metastatic potential of tumor cells by regulating the genes involved in the breakdown of the ECM (extracellular matrix) as well as genes that control motility and adhesion of tumor cells. HIF activity is upregulated by mutated RAS, a member of the KRAS family of oncogenes, and BRAF (v-raf murine sarcoma viral oncogene homolog B1) as well as loss-of-function mutations of the PTEN gene. PTEN (phosphatase and tensin homolog), which is missing in 60% to 70% of metastatic cancers in humans, is the name of a phospholipid phosphatase protein, and gene that encodes it. The PTEN gene acts as a tumor suppressor gene thanks to the role of its protein product in regulation of the cycle of cell division, preventing cells from growing and dividing too rapidly.

Investigators at the University of North Carolina (Chapel Hill, USA) examined the molecular basis for melanoma metastasis in a genetically engineered PTEN-deficient, BRAF-mutant mouse model. In this model the activities of HIF1 and HIF2, which are usually overexpressed in melanoma tumors, can be shut down.

Results published in the April 8, 2013, online edition of the Journal of Clinical Investigation revealed that inactivation of HIF1 or HIF2 prevented metastasis without affecting primary tumor formation. Both HIF1 and HIF2 independently activated the proto-oncogene tyrosine-protein kinase SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)) using different signaling pathways.

The protein encoded by the SRC gene has been linked to several different cancers, and the identification of its role in melanoma may mean that existing drugs that target SRC may be adapted for treatment of malignant melanoma.

“What we are trying to do now is inhibit these pathways with drugs in the mice to see if we see a decrease of metastasis,” said first author Sara Hanna, a graduate student researcher at the University of North Carolina.

Related Links:

University of North Carolina




Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.